Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRSI to Predict Early Response to RT/TMZ ± Belinostat in Newly-Diagnosed Glioblastomas
NCT02137759Phase 2Completed
- Sponsor
- Emory University
- Start
- May 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belinostat in glioblastoma multiforme (GBM), sponsored by Emory University. Started May 2014; status: completed.
02
Drugs
belinostat
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02137759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137759.